RxDoctor Payments Data

Gregory Austin, MD

Orthopaedic Surgery · Cranston, RINPI 1285620138

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Pacira Therapeutics, Inc. at 42.0% of the total. Reporting peaked in 2019 at $196 and has fallen 88.0% since, to $23 in 2023. That places this record below the midpoint for orthopaedic surgery clinicians in RI, where the typical reported total is $2,875.

$569in general payments, 2019–2025

Across 33 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Therapeutics, Inc.$239
  • Amgen$56
  • Endo Pharmaceuticals Inc.$50
  • Zyla Life Sciences, Inc.$43
  • Integra Lifesciences Corporation$39
  • E.r. Squibb & Sons, L.L.C.$34
  • plus $108 from 6 others

What the payments were for

  • Food & beverage$569100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$569 in reported general payments places this provider in the 20th percentile of 124 orthopaedic surgery providers in Rhode Island.

See all orthopaedic surgery providers in Rhode Island →

Medicare billing

Part B allowed, 2024
$87,703
Medicare patients
153
Services billed
1,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiaflexCollagenase Clostridium Hist.14$127,042
Ibuprofen15$215
Celecoxib12$211
Naproxen12$142
Meloxicam28$136
Prednisone21$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Endo Pharmaceuticals Inc.Xiaflex$50$127,04214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 124 orthopaedic surgery providers in Rhode Island.

Other orthopaedic surgery in Cranston

See the full list for Rhode Island →

Where these figures come from

Is this you, or does something look wrong? →